Actively Recruiting
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Led by Effector Therapeutics · Updated on 2024-05-21
30
Participants Needed
14
Research Sites
283 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
CONDITIONS
Official Title
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histological or cytological confirmation of breast cancer or selected advanced solid tumors
- Metastatic or locoregionally recurrent disease refractory or intolerant to standard therapies
- Prior chemotherapy, endocrine therapy, or other treatment for advanced/metastatic disease with at least one but no more than five prior lines
- Recurrence or progression after at least one line of endocrine therapy in advanced/metastatic setting
- Prior treatment with a CDK4/6 inhibitor
- Tumor is estrogen receptor positive (ER IHC staining > 0%) for breast cancer cohorts
- Specific genetic or biomarker status depending on cohort (e.g., FGFR amplification, HER2 status, KRAS mutations)
You will not qualify if you...
- KRAS G12C mutations in relevant cohorts
- Prior treatment with KRAS-specific therapy in certain cohorts
- Patients who have not undergone platinum-based chemotherapy and anti-PD-1/L1 agent treatment when appropriate
- Patients who have progressed after approved anti-HER2 agents and chemotherapy are included only in specific cohorts
- Patients intolerant to approved therapies may be excluded unless discussed with Medical Monitor
- Maximum of five prior lines of therapy for advanced/metastatic disease exceeded
- Absence of required tumor biomarker status for the cohort (e.g., ER negativity when ER+ required)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
University of Southern California
Los Angeles, California, United States, 90033
Actively Recruiting
2
Valkyrie Clinical Trials
Los Angeles, California, United States, 90067
Actively Recruiting
3
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States, 92663
Completed
4
Stanford University
Palo Alto, California, United States, 94304
Actively Recruiting
5
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
6
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States, 89169
Completed
7
Memorial Sloan Kettering Cancer Center- Monmouth
Middletown, New Jersey, United States, 07748
Actively Recruiting
8
Memorial Sloan Kettering Cancer Center- Commack
Commack, New York, United States, 11725
Actively Recruiting
9
Memorial Sloan Kettering Cancer Center- Westchester
Harrison, New York, United States, 10604
Actively Recruiting
10
Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care
New York, New York, United States, 11101
Actively Recruiting
11
University of Toledo Medical Center
Toledo, Ohio, United States, 43614
Completed
12
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
13
New Experimental Therapeutics of San Antonio - NEXT Oncology
San Antonio, Texas, United States, 78229
Completed
14
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
M
Mark Densel
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
11
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here